Clinical Research Directory

Inclusion Criteria: * Male subject aged 18-41 years old with skin type I to IV according to the Fitzpatrick scale; * Affected by androgenetic alopecia with hair loss evaluated grade IIA to IV the modified Norwood-Hamilton scale; * Subject with chestnut brown, dark or black hair; * Subject with hair length ≥ 3 cm on the vertex and agreeing to keep this minimum length for the duration of the study; * Subject agreeing to have a shaved zone of 1.5 cm² on scalp area; * Subject accepting not to dye, bleach his hair or to do a permanent wave during the whole study duration; * Subject accepting to use condoms if her partner is pregnant. Exclusion Criteria: * Female subject; * Subject presenting a life-threatening endocrine disease, neoplasia or other serious diseases; * Subjects suffering from chemo-induced alopecia (poisoning, medicines), or resulting from a chronic disease (genetic, endocrine, immunological, deficiencies), seasonal hair loss; * Subject having any other concomitant dermatological affection of the scalp (psoriasis, seborrheic dermatitis, eczema, other alopecia than androgenetic); * Subject suffering from a recurrent, acute, non-stabilized or evolving disease judged by the investigator able to interfere with the study needs and hair growth; * Subject having had surgical intervention for capillary correction (e.g., hair transplant) or intending to have recourse to this surgery during the entire study period; * Subject presenting a hypersensitivity to any of the components of the finasteride medication or to any 5-alpha-reductase inhibitor; * Subject that has applied or taken prior to the start of the study (screening) interfering drugs or products * Subject taking any other medical treatment (topic or per os) likely to interfere on hair growth or hair loss within 6 months prior to the screening visit; * Subject following a long period (\>30 days) treatment of anti-inflammatory within 4 months prior to the start of the study (screening visit); * Subject taking topic cosmetic treatment or per os nutritional supplement likely to interfere on hair growth or hair loss during the last 3 months prior to the screening visit; * Subject having a topical or oral route treatment of the scalp (anti-seborrheic, anti-dandruff, daily friction) within 2 weeks prior to the screening visit; * Subject who has been exposed within one month prior to the screening visit in an intense or excessive manner to sun (natural or artificial) or during the study; * Subject having a wig or hair extension; * Protected subject as defined in the Articles of the French Public Health Code. Article 1121-7: person deprived of liberty by a judicial or administrative decision, or subject to psychiatric care, or person admitted to a health or social institution for purposes other than the research. Article 1121-8: adult person subject to a legal protection measure or unable to express his/her consent; * Subject unable to communicate or cooperate with the Investigator due to poor mental development, language problems or impaired cerebral function; * Subject currently participating in another clinical study or being in an exclusion period of another clinical study;